Kezar Life Sciences, Inc. (KZR) Profit After Tax (2017 - 2026)

Kezar Life Sciences has reported Profit After Tax for 10 years, with the latest figure at -$5.8 million in Q1 2026.

• Quarterly Profit After Tax rose 65.23% year-over-year to -$5.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$45.2 million (up 42.48% YoY) and the FY2025 annual result came in at -$56.0 million, up 33.08% from the prior year.
• Profit After Tax climbed to -$5.8 million in Q1 2026 per KZR's latest filing, from -$14.5 million in the prior quarter.
• Over five years, Profit After Tax peaked at -$5.8 million in Q1 2026 and troughed at -$32.3 million in Q4 2023.
• A 5-year average of -$18.6 million and a median of -$18.2 million in 2022 frame the typical range for Profit After Tax.
• The sharpest annual moves came in 2023 and 2026: Profit After Tax plunged 77.44% in 2023, then surged 65.23% in 2026.
• Over 5 years, Profit After Tax stood at -$18.2 million in 2022, then slumped by 77.44% to -$32.3 million in 2023, then jumped by 37.33% to -$20.2 million in 2024, then advanced by 28.05% to -$14.5 million in 2025, then surged by 60.43% to -$5.8 million in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered -$5.8 million, -$14.5 million, and -$11.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.